Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 12

HOS-112073 · Präparat HOS-093615

No significant effect on atazanavir concentrations was observed when administered with enteric-coated didanosine, but administration with food decreased didanosine concentrations. Tenofovir disoproxil fumarate Atazanavir AUC: ↓22% (↓35% ↓6%) * When co-administered with 300 mg once daily Atazanavir Cmax: ↓16% (↓30% ↔0%) * tenofovir disoproxil fumarate, it is (atazanavir 300 mg once daily Atazanavir Cmin: ↓23% (↓43% ↑2%) * recommended that REYATAZ with ritonavir 100 mg once daily) 300 mg be given with ritonavir * In a combined analysis from several 100 mg and tenofovir disoproxil 300 mg tenofovir disoproxil clinical studies, atazanavir/ritonavir fumarate 300 mg (all as a single fumarate is equivalent to 245 mg 300/100 mg co-administered with dose with food). tenofovir disoproxil. tenofovir disoproxil fumarate 300 mg (n = 39) was compared to Studies conducted in HIV- atazanavir/ritonavir 300/100 mg (n = 33). infected patients The efficacy of REYATAZ/ritonavir in combination with tenofovir disoproxil fumarate in treatment-experienced patients has been demonstrated in clinical study 045 and in treatment naïve patients in clinical study 138 (see sections 4.8 and 5.1). The mechanism of interaction between atazanavir and tenofovir disoproxil fumarate is unknown. Tenofovir disoproxil fumarate Tenofovir disoproxil fumarate AUC: ↑37% Patients should be closely 300 mg once daily (↑30% ↑45%) monitored for tenofovir disoproxil (atazanavir 300 mg once daily Tenofovir disoproxil fumarate Cmax: ↑34% fumarate-associated adverse with ritonavir 100 mg once daily) (↑20% ↑51%) reactions, including renal disorders. Tenofovir disoproxil fumarate Cmin: ↑29% 300 mg tenofovir disoproxil (↑21% ↑36%) fumarate is equivalent to 245 mg tenofovir disoproxil. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg once daily Atazanavir (pm): all administered with Co-administration of efavirenz and (atazanavir 400 mg once daily food REYATAZ is not recommended with ritonavir 100 mg once daily) Atazanavir AUC: ↔0%(↓9% ↑10%)* (see section 4.4). Atazanavir Cmax: ↑17%(↑8% ↑27%)* Atazanavir Cmin: ↓42%(↓51% ↓31%)* Efavirenz 600 mg once daily Atazanavir (pm): all administered with (atazanavir 400 mg once daily food with ritonavir 200 mg once daily) Atazanavir AUC: ↔6% (↓10% ↑26%)*/** Atazanavir Cmax: ↔9% (↓5% ↑26%)*/** Atazanavir Cmin: ↔12% (↓16% ↑49%)*/** *When compared to REYATAZ 300 mg/ritonavir 100 mg once daily in the evening without efavirenz. This decrease in atazanavir Cmin might negatively impact the efficacy of atazanavir. The mechanism of efavirenz/atazanavir interaction is CYP3A4 induction.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) didanosine (HOS-085836) fumarate (HOS-108845) efavirenz (HOS-087947) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521)